Inactive Instrument

Vitro Diagnostics, Inc.

VODG

US9285013036

Vitro Biopharma, Inc. amended terms of the transaction

January 22, 2023

As of January 23, 2023, the company has receive $405,000 in its first tranche. The transaction included participation from five investors.

Latest news about Vitro Diagnostics, Inc.

Vitro Biopharma, Inc. announced that it has received $0.175 million in funding	Apr. 10	CI
Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	Mar. 14	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	Jan. 29	CI
Vitro Biopharma, Inc. Announces Chief Financial Officer Changes	Jan. 23	CI
Vitro Biopharma, Inc. announced that it has received $1 million in funding	Jan. 09	CI
Vitro Biopharma, Inc. announced a financing transaction	Nov. 15	CI
Vitro Biopharma, Inc. announced that it expects to receive $2 million in funding	Nov. 15	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	23-08-28	CI
Vitro Biopharma, Inc. announced that it has received $0.1 million in funding	23-07-12	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	23-06-13	CI
Vitro Biopharma, Inc. announced that it has received $0.325 million in funding	23-06-12	CI
Vitro Biopharma, Inc. announced that it has received $0.1 million in funding	23-06-04	CI
Vitro Biopharma, Inc. announced that it has received $0.2 million in funding	23-04-13	CI
Vitro Biopharma, Inc. announced that it expects to receive CAD 0.2376 million in funding	23-03-14	CI
Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	23-03-14	CI
Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	23-03-14	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2022	23-01-30	CI
Vitro Biopharma, Inc. Auditor Raises 'Going Concern' Doubt	23-01-29	CI
Vitro Biopharma, Inc. amended terms of the transaction	23-01-22	CI
Vitro Biopharma, Inc. announced a financing transaction	23-01-05	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022	22-11-03	CI
Vitro Biopharma, Inc. has filed an IPO in the amount of $17.25 million.	22-09-09	CI
Vitro Biopharma Inc. Auditor Raises 'Going Concern' Doubt	22-09-08	CI
Vitro Biopharma Inc. announced a financing transaction	21-10-14	CI
Vitro Biopharma Inc. acquired INFINIVIVE MD STEM CELL TECHNOLOGIES for $5.8 million.	21-08-30	CI

Vitro Diagnostics, Inc., doing business as Vitro Biopharma, is engaged in the development, manufacturing and distribution of stem cell products and related tools for use in research, drug discovery and clinical trials. The Company's clinical products include clinical grade MSC-Gro for mesenchymal stem cell (MSC) expansion prior to transplantation; an equine MSC cell line with application to treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, and others; testing and therapies related to endogenous stem cell activation; diagnostic testing of stem cell activation and determination of stem cell functional status, and cell-based assays for discovery of stem cell activation agents and new drugs for the treatment of osteoporosis. The Company offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
SAMSUNG BIOLOGICS CO.,LTD.	+1.45%	40.51B
BIOGEN INC.	-15.94%	31.67B
UCB	+52.66%	24.62B
BIOMARIN PHARMACEUTICAL INC.	-14.50%	15.65B
INCYTE CORPORATION	-14.38%	12.07B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.97B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+4.87%	8.81B
INNOVENT BIOLOGICS, INC.	-4.33%	8.5B

Biopharmaceuticals